Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| SRPT | Sarepta Therapeutics | $16.66 | -$7.79 | -31.88% | 14.4M | $2.4B | $10.42$138.81 |
| ICHR | Ichor | $15.95 | -$6.97 | -30.41% | 1.5M | $786.8M | $13.12$36.48 |
| JELD | Jeld-wen | $2.94 | -$1.26 | -30.00% | 4.8M | $358.7M | $2.31$11.66 |
| NOMA | Nomadar | $8.33 | -$3.17 | -27.57% | 49.2K | - | $2.00$57.70 |
| CJET | Chijet Motor | $2.97 | -$0.86 | -22.45% | 198K | $350.4M | $2.77$299.00 |
| FORD | Forward Industries | $10.95 | -$3.03 | -21.67% | 1.3M | $1.2B | $3.32$46.00 |
| FHTX | Foghorn Therapeutics | $3.34 | -$0.87 | -20.66% | 164.9K | $238.0M | $2.94$9.70 |
| SLDB | Solid Biosciences | $4.15 | -$1.06 | -20.29% | 953K | $404.9M | $2.41$7.37 |
| MYGN | Myriad Genetics | $6.55 | -$1.63 | -19.93% | 1.2M | $761.1M | $3.76$19.60 |
| ADTX | Aditxt | $5.23 | -$1.28 | -19.66% | 74.2K | $32.4M | $5.15$14,966.85 |
Related Articles
Featured Article
Is This Stock a Buy After Soaring by 20% in 1 Day?
Prosper Junior Bakiny|Jul 24, 2025
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?
Cory Renauer|Dec 15, 2024
After a Big Win, Is Sarepta Therapeutics Stock a Buy?
Alex Carchidi|Jul 6, 2024
One key issue remains unresolved, and it could be a significant one.
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?
David Jagielski|Jul 4, 2024
The label expansion paves the way for much more revenue growth for Sarepta in the years ahead.
1 Soaring Growth Stock to Buy and Hold for 10 Years
Prosper Junior Bakiny|Jul 3, 2024
Let's look beyond the biotech's performance this year.
1 Top Growth Stock to Buy and Hold for 10 Years
Prosper Junior Bakiny|May 1, 2024
This company's lineup might look very different in a decade, but the end result will be the same for investors.
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
Alex Carchidi|Mar 13, 2024
The threat is still emerging, but it could be significant.
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
Alex Carchidi|Mar 4, 2024
The upcoming regulatory decision on its latest drug could be big.
Is It Too Late to Buy Sarepta Therapeutics Stock?
Prosper Junior Bakiny|Feb 28, 2024
The company's hyperfocus on its core area could continue to be highly lucrative.
2 Magnificent Growth Stocks to Buy With $500
Prosper Junior Bakiny|Feb 15, 2024
No need to break the bank to invest in promising stocks.
